286946-24-5

Usage

Uses

Methyl 3,6-dichloro-pyridazine-4-carboxylate

Upstream product

• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 

Downstream Products

• 1007571-73-4 6-chloro-3-(2,4-difluorophenoxy)pyridazine-4-carboxylic acid methyl ester 
• 50681-26-0 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid 
• 89581-64-6 methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate 
• 1204400-37-2 C₁₃H₉ClF₂N₂O₃ 
• 1204400-38-3 C₁₂H₇ClF₂N₂O₃ 
• 1345443-39-1 C₁₃H₁₀F₂N₂O₄ 
• 1591827-16-5 methyl 6-chloro-3-methoxy-pyridazine-4-carboxylate 
• 1591826-32-2 3-chloro-5-((1-((6-(difluoromethyl)-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-90-5 3-chloro-5-((1-((6-(difluoromethyl)-3-methoxypyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-89-2 3-chloro-5-((1-((6-formyl-3-methoxypyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-88-1 3-chloro-5-((1-((6-(hydroxymethyl)-3-methoxypyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-87-0 3-chloro-5-((1-((3-methoxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-79-0 3-chloro-5-((1-((6-chloro-3-methoxypyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 89380-13-2 6-chloro-4-(chloromethyl)-3-methoxypyridazine 

Relevant academic research and scientific papers

N-LINKED GLYCOSYLATION INHIBITORS AND METHODS OF USING SAME

The present disclosure includes compounds, compositions, and methods for preventing or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound and/or pharmaceutical composition of the disclosure.

PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based o